Group A Streptococcus

Seminars in Pediatric Infectious Diseases

Volumn 17, Issue 3, 2006, Pages 140-148

  Martin, Judith M ^a   Green, Michael ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BENZATHINE PENICILLIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFAZOLIN; CEFDINIR; CEFIXIME; CEFUROXIME AXETIL; CEPHALOSPORIN; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; CORTICOSTEROID; DICLOXACILLIN; ERYTHROMYCIN; ERYTHROMYCIN ESTOLATE; ERYTHROMYCIN ETHYLSUCCINATE; IMMUNOGLOBULIN; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXACILLIN; PENICILLIN V POTASSIUM; RIFAMPICIN; UNINDEXED DRUG;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELL SURFACE; CELLULITIS; ECTHYMA; ERYSIPELAS; GLOMERULONEPHRITIS; HUMAN; IMPETIGO; NECROTIZING FASCIITIS; NONHUMAN; PHAGOCYTOSIS; PHARYNGITIS; RHEUMATIC FEVER; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

ANTI-BACTERIAL AGENTS; CELLULITIS; CHILD, PRESCHOOL; FASCIITIS, NECROTIZING; GLOMERULONEPHRITIS; HUMANS; INFANT; PHARYNGITIS; RHEUMATIC FEVER; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 33747799642     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.spid.2006.07.001     Document Type: Article

References (78)

1. Kaplan E.L., Johnson D.R., Del Rosario M.C., et al. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics. examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr Infect Dis J 18 (1999) 1069-1072
2. Dias R., Louro D., and Canica M. Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period. Antimicrob Agents Chemother 50 (2006) 2098-2105
3. Hotomi M., Billal D.S., Shimada J., et al. Current status of antimicrobial susceptibility of clinical isolates of Streptococcus pyogenes in Japan. report of a countrywide surveillance study. J Infect Chemother 11 (2005) 48-51
4. Maruyama S., Yoshioka H., Fujita K., et al. Sensitivity of group A streptococci to antibiotics. Prevalence of resistance to erythromycin in Japan. Am J Dis Child 133 (1979) 1143-1145
5. Seppala H., Nissinen A., Jarvinen H., et al. Resistance to erythromycin in group A streptococci. N Engl J Med 326 (1992) 292-297
6. Martin J.M., Green M., Barbadora K.A., et al. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 346 (2002) 1200-1206
7. Green M., Martin J.M., Barbadora K.A., et al. Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania. Antimicrob Agents Chemother 48 (2004) 473-476
8. White C.B., Bass J.W., and Yamada S.M. Rapid latex agglutination compared with the throat culture for the detection of group A streptococcal infection. Pediatr Infect Dis 5 (1986) 208-212
9. Tanz R.R., and Shulman S.T. Pharyngitis. In: Long S.S., Pickering L.K., and Prober C.G. (Eds). Principles and Practices of Pediatric Infectious Diseases (1997), Churchill Livingstone, New York, NY 200-207
10. Pichichero M.E., Disney F.A., Green J.L., et al. Comparative reliability of clinical, culture, and antigen detection methods for the diagnosis of group A beta-hemolytic streptococcal tonsillopharyngitis. Pediatr Ann 21 (1992) 798-805
11. Wald E.R. Expanded role of group A streptococci in children with upper respiratory infections. Pediatr Infect Dis J 18 (1999) 663-665
12. Breese B.B. A simple scorecard for the tentative diagnosis of streptococcal pharyngitis. Am J Dis Child 131 (1977) 514-517
13. Wald E.R., Green M.D., Schwartz B., et al. A streptococcal score card revisited. Pediatr Emerg Care 14 (1998) 109-111
14. Poses R.M., Cebul R.D., Collins M., et al. The accuracy of experienced physicians' probability estimates for patients with sore throats. Implications for decision making. JAMA 254 (1985) 925-929
15. McIsaac W.J., Kellner J.D., Aufricht P., et al. Empirical validation of guidelines for the management of pharyngitis in children and adults. JAMA 291 (2004) 1587-1595
16. Group A Streptococcal Infections. Red Book Report of the Committee on Infectious Diseases. ed 26 (2003), American Academy of Pediatrics, Elk Grove Village, IL pp 573-584
17. Nelson J.D. The effect of penicillin therapy on the symptoms and signs of streptococcal pharyngitis. Pediatr Infect Dis 31 (1984) 10-13
18. Brink W., Rammelkamp C.J.R., Denny F.W., et al. Effect in penicillin and aureomycin on the natural course of streptococcal tonsillitis and pharyngitis. Am J Med 10 (1951) 300-308
19. Rammelkamp C.J., and Weaver R. Acute glomerulonephritis, the significance of the variations in the incidence of the disease. J Clin Invest 32 (1953) 345-358
20. Bisno A.L., Gerber M.A., Gwaltney Jr. J.M., et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 35 (2002) 113-125
21. Dajani A., Taubert K., Ferrieri P., et al., Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever. a statement for health professionals. Pediatrics 96 (1995) 758-764
22. Snow V., Mottur-Pilson C., and Gonzales R. Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. Ann Intern Med 134 (2001) 518-520
23. Bass J.W., Crast F.W., Knowles C.R., et al. Streptococcal pharyngitis in children. A comparison of four treatment schedules with intramuscular penicillin G benzathine. JAMA 235 (1976) 1112-1116
24. Coonan K.M., and Kaplan E.L. In vitro susceptibility of recent North American group A streptococcal isolates to eleven oral antibiotics. Pediatr Infect Dis J 13 (1994) 630-635
25. Gerber M.A., Spadaccini L.J., Wright L.L., et al. Twice-daily penicillin in the treatment of streptococcal pharyngitis. Am J Dis Child 139 (1985) 1145-1148
26. Feder Jr. H.M., Gerber M.A., Randolph M.F., et al. Once-daily therapy for streptococcal pharyngitis with amoxicillin. Pediatrics 103 (1999) 47-51
27. Shvartzman P., Tabenkin H., Rosentzwaig A., et al. Treatment of streptococcal pharyngitis with amoxycillin once a day. BMJ 306 (1993) 1170-1172
28. Lan A.J., Colford J.M., and Colford Jr. J.M. The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis. a meta-analysis. Pediatrics 105 (2000) E19
29. Green M., Allen C., Beall B., et al. Molecular Epidemiology of Macrolide Resistant (MR) Group A Streptococci (GAS) in the US. Results of Multicenter Surveillance (2002-2003). (2004) The 42nd Annual Meeting of IDSA, Boston, MA September 30 to October 3, (abstr 343)
30. Fujita K., Murono K., Yoshikawa M., et al. Decline of erythromycin resistance of group A streptococci in Japan. Pediatr Infect Dis J 13 (1994) 1075-1078
31. Tanz R.R., Shulman S.T., Shortridge V.D., et al. Community-based surveillance in the United States of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons. Clin Infect Dis 39 (2004) 1794-1801
32. Casey J.R., and Pichichero M.E. Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children. Pediatrics 113 (2004) 866-882
33. Pichichero M.E., and Margolis P.A. A comparison of cephalosporins and penicillins in the treatment of group A beta-hemolytic streptococcal pharyngitis. a meta-analysis supporting the concept of microbial copathogenicity. Pediatr Infect Dis J 10 (1991) 275-281
34. Shulman S.T., and Gerber M.A. So what's wrong with penicillin for strep throat?. Pediatrics 113 (2004) 1816-1819
35. Gerber M.A., and Tanz R.R. New approaches to the treatment of group A streptococcal pharyngitis. Curr Opin Pediatr 13 (2001) 51-55
36. Klein J.O. Management of streptococcal pharyngitis. Pediatr Infect Dis J 13 (1994) 572-575
37. Tanz R.R., Shulman S.T., Barthel M.J., et al. Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. J Pediatr 106 (1985) 876-880
38. Kaplan E.L., and Johnson D.R. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group a streptococci from children with acute pharyngitis. Pediatrics 108 (2001) 1180-1186
39. Smith T.D., Huskins W.C., Kim K.S., et al. Efficacy of beta-lactamase-resistant penicillin and influence of penicillin tolerance in eradicating streptococci from the pharynx after failure of penicillin therapy for group A streptococcal pharyngitis. J Pediatr 110 (1987) 777-782
40. Roos K., Grahn E., and Holm S.E. Evaluation of beta-lactamase activity and microbial interference in treatment failures of acute streptococcal tonsillitis. Scand J Infect Dis 18 (1986) 313-319
41. Gerber M.A. Treatment failures and carriers. perception or problems?. Pediatr Infect Dis J 13 (1994) 576-579
42. Kaplan E.L., Gastanaduy A.S., and Huwe B.B. The role of the carrier in treatment failures after antibiotic for group A streptococci in the upper respiratory tract. J Lab Clin Med 98 (1981) 326-335
43. Paradise J.L., Bluestone C.D., Bachman R.Z., et al. Efficacy of tonsillectomy for recurrent throat infection in severely affected children. Results of parallel randomized and nonrandomized clinical trials. N Engl J Med 310 (1984) 674-683
44. Tanz R.R., Poncher J.R., Corydon K.E., et al. Clindamycin treatment of chronic pharyngeal carriage of group A streptococci. J Pediatr 119 (1991) 123-128
45. Bliss D.Z., Johnson S., Savik K., et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 129 (1998) 1012-1019
46. Hirschhorn L.R., Trnka Y., Onderdonk A., et al. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 169 1 (1994) 127-133
47. Nelson D., Loomis L., and Fischetti V.A. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 98 (2001) 4107-4112
48. Ferrieri P., Dajani A.S., Wannamaker L.W., et al. Natural history of impetigo. I. Site sequence of acquisition and familial patterns of spread of cutaneous streptococci. J Clin Invest 51 (1972) 2851-2862
49. Bisno A.L., and Stevens D.L. Streptococcal infections of skin and soft tissues. N Engl J Med 334 (1996) 240-245
50. McGregor K.F., Spratt B.G., Kalia A., et al. Multilocus sequence typing of Streptococcus pyogenes representing most known emm types and distinctions among subpopulation genetic structures. J Bacteriol 186 (2004) 4285-4294
51. McDonald M., Currie B.J., and Carapetis J.R. Acute rheumatic fever. a chink in the chain that links the heart to the throat?. Lancet Infect Dis 4 (2004) 240-245
52. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. JAMA 268 (1992) 2069-2073
53. American Heart Association. Jones criteria (revised) for guidance in the diagnosis of rheumatic fever. Circulation 69 (1984) 108A-204A
54. Zangwill K.M., Wald E.R., and Londino Jr. A.V. Acute rheumatic fever in western Pennsylvania. a persistent problem into the 1990s. J Pediatr 118 (1991) 561-563
55. Miner L.J., Petheram S.J., Daly J.A., et al. Molecular characterization of Streptococcus pyogenes isolates collected during periods of increased acute rheumatic fever activity in Utah. Pediatr Infect Dis J 23 (2004) 56-61
56. Richter S.S., Heilmann K.P., Beekmann S.E., et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 41 (2005) 599-608
57. Cleary P.P., Kaplan E.L., Handley J.P., et al. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet 339 (1992) 518-521
58. Congeni B.L. The resurgence of acute rheumatic fever in the United States. Pediatr Ann 21 (1992) 816-820
59. Bisno A., and Stevens D. Streptococcus pyogenes (including streptococcal toxic shock syndrome and necrotizing fasciitis). (2000) 2101-2116
60. Brundage J.F., Gunzenhauser J.D., Longfield J.N., et al. Epidemiology and control of acute respiratory diseases with emphasis on group A beta-hemolytic streptococcus. a decade of U.S. Army experience. Pediatrics 97 (1996) 964-970
61. Gunzenhauser J.D., Longfield J.N., Brundage J.F., et al. Epidemic streptococcal disease among Army trainees, July 1989 through June 1991. J Infect Dis 172 (1995) 124-131
62. Markowitz M. Changing epidemiology of group A streptococcal infections. Pediatr Infect Dis J 13 (1994) 557-560
63. Stetson C., Rammelkamp C.J., Krause R., et al. Epidemic acute nephritis. studies on etiology, natural history and prevention. Medicine 34 (1955) 431-450 (Baltimore)
64. Clark G., White R.H., Glasgow E.F., et al. Poststreptococcal glomerulonephritis in children. clinicopathological correlations and long-term prognosis. Pediatr Nephrol 2 (1988) 381-388
65. Centers for Disease Control and Prevention DoBaMD. Streptococcus pyogenes emm sequence database. Available at: http://www.cdc.gov/ncidod/biotech/strep/emmtypes.htm. Accessed July 14, 2006
66. Committee on Infectious Diseases. Severe invasive group A Streptococcal infections. a subject review. Pediatrics 101 (1998) 136-140
67. Stevens D.L., Tanner M.H., Winship J., et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 321 (1989) 1-7
68. Zimbelman J., Palmer A., and Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 18 (1999) 1096-1100
69. Stevens D.L., Gibbons A.E., Bergstrom R., et al. The Eagle effect revisited. efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 158 (1988) 23-28
70. Stevens D., Bryant A., and Yan S. Invasive group A streptococcal infection. new concepts in antibiotic treatment. Int J Antimicrob Agents 4 (1994) 297-301
71. Kaul R., McGeer A., Norrby-Teglund A., et al., The Canadian Streptococcal Study Group. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-a comparative observational study. Clin Infect Dis 28 (1999) 800-807
72. Ballow M. Mechanisms of action of intravenous immune serum globulin therapy. Pediatr Infect Dis J 13 (1994) 806-811
73. Ellis M.W., and Lewis J.S. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 18 6 (2005) 496-501
74. Riseman J.A., Zamboni W.A., Curtis A., et al. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery 108 (1990) 847-850
75. Jallali N., Withey S., and Butler P.E. Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am J Surg 189 (2005) 462-466
76. McArthur J.D., and Walker M.J. Domains of group A streptococcal M protein that confer resistance to phagocytosis, opsonization and protection. implications for vaccine development. Mol Microbiol 59 (2006) 1-4
77. Park H.S., and Cleary P.P. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun 73 (2005) 7878-7886
78. McNeil S.A., Halperin S.A., Langley J.M., et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 41 (2005) 1114-1122